Polygenic risk scores for prostate cancer: testing considerations

Area of Science:

• Genetics
• Oncology
• Epidemiology

Background:

• Genome-wide association studies (GWAS) have identified over 170 single nucleotide variants (SNVs) linked to prostate cancer risk.
• Individual SNVs confer only minor increases in risk and are insufficient for predicting overall prostate cancer development.
• Polygenic risk scores (PRS) aggregate the effects of multiple SNVs.

Purpose of the Study:

• To review the current status of polygenic risk scores (PRS) for prostate cancer.
• To discuss the clinical utility and testing considerations for PRS in prostate cancer risk assessment.

Main Methods:

• Review of existing literature on GWAS and PRS for prostate cancer.
• Analysis of the predictive capabilities of PRS in conjunction with established risk factors like PSA.
• Examination of current clinical availability and implementation of PRS.

Main Results:

• PRS integrate information from numerous SNVs, offering a potentially more comprehensive risk assessment than individual variants.
• PRS may augment the predictive power of established biomarkers such as prostate-specific antigen (PSA).
• Clinical availability of PRS for prostate cancer is increasing, necessitating clear guidelines for their use.

Conclusions:

• Polygenic risk scores represent a significant advancement in leveraging genomic data for prostate cancer risk stratification.
• Further research and clinical validation are essential to optimize the integration of PRS into routine prostate cancer screening and management.
• Understanding the nuances of PRS, including testing considerations, is crucial for healthcare providers and patients.